

June 19, 2018

# CymaBay Therapeutics to Host Analyst and Investor Day on June 26, 2018

NEWARK, Calif., June 19, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, will host an analyst and investor day on June 26, 2018 from 12:00pm to 2:00pm Eastern Time in New York City. Members of CymaBay's senior management team will provide an update on the company's clinical development of seladelpar in patients with primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH).

The meeting will also feature presentations by prominent liver experts Dr. Christopher Bowlus, UC Davis Health, Dr. Stephen Harrison, Pinnacle Clinical Research, and Dr. Gideon Hirschfield, University of Birmingham, UK, who will discuss their perspectives on current and novel approaches to treating PBC and NASH.

Seladelpar is an orally administered potent and selective peroxisome proliferator-activated receptor delta (PPAR $\delta$ ) agonist. CymaBay presented new data from its ongoing Phase 2 study of seladelpar in patients with PBC at The International Liver Congress™ 2018 and recently announced the initiation of a Phase 2b study of seladelpar in patients with NASH.

This event is intended for institutional investors, sell-side analysts, investment bankers, and business development professionals only. Please [RSVP](#) in advance if you plan to attend, as space is limited. For those who are unable to attend in person, a live webcast and replay will be accessible on the Investors section of the CymaBay website at <http://ir.cymabay.com/events>.

## About CymaBay

CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. Seladelpar is a potent, selective, orally active PPAR $\delta$  agonist, currently in development for the treatment of patients with primary biliary cholangitis (PBC), an autoimmune liver disease, and with non-alcoholic steatohepatitis (NASH).

## Cautionary Statements

The statements in this press release regarding the potential for seladelpar to treat PBC and NASH, the potential benefits to patients, CymaBay's expectations and plans regarding future clinical trials and CymaBay's ability to fund current and planned clinical trials are forward looking statements that are subject to risks and uncertainties. Actual results and the timing of events regarding the further development of seladelpar could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties, which include, without limitation, risks related to: the success, cost and timing of any of CymaBay's product development activities, including clinical trials; effects observed in trials to date that may not be repeated in the future; any delays or inability to obtain or maintain regulatory

approval of CymaBay's product candidates in the United States or worldwide; and the ability of CymaBay to obtain sufficient financing to complete development, regulatory approval and commercialization of its product candidates in the United States and worldwide. Additional risks relating to CymaBay are contained in CymaBay's filings with the Securities and Exchange Commission, including without limitation its most recent Annual Report on Form 10-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. CymaBay disclaims any obligation to update these forward-looking statements except as required by law.

For additional information about CymaBay, visit [www.cymabay.com](http://www.cymabay.com).

**Contact:**

Hans Vitzthum  
LifeSci Advisors, LLC  
212-915-2568  
[Hans@LifeSciAdvisors.com](mailto:Hans@LifeSciAdvisors.com)



Source: CymaBay Therapeutics, Inc.